Investigational Drug Information for Lazertinib
✉ Email this page to a colleague
What is the drug development status for Lazertinib?
Lazertinib is an investigational drug.
There have been 32 clinical trials for Lazertinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 30th 2020.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Brain Neoplasms. The leading clinical trial sponsors are Janssen Research & Development, LLC, Yuhan Corporation, and Yonsei University.
Summary for Lazertinib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 42 |
| WIPO Patent Applications | 42 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 1 (2020-09-30) |
| Vendors | 40 |
Recent Clinical Trials for Lazertinib
| Title | Sponsor | Phase |
|---|---|---|
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | Janssen Research & Development, LLC | Phase 2 |
| Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment | Samsung Medical Center | Phase 2 |
| A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker | National Cancer Center, Korea | Phase 2 |
Clinical Trial Summary for Lazertinib
Top disease conditions for Lazertinib
Top clinical trial sponsors for Lazertinib
US Patents for Lazertinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
